On April 7, 2020, Parallax Health Sciences, Inc. executed an Executive Agreement for the appointment of Dr. David L. Stark as the company’s President, pursuant to a resolution of the board of directors effective March 1, 2020. In connection with the appointment, Mr. Paul R. Arena, who has held the position of President since July 2017, remains the company’s Chief Executive Officer and Chairman of the Board of Directors, but resigned the position of President to afford Dr. Stark’s appointment. Dr. Stark has 18 years’ experience in the medical and clinical fields, from the toxicology labs to the investigator site, and has been essential to all aspects of clinical and device research. Due to his extensive and broad experiences in the inner workings of the research and regulatory aspects of clinical trials, Dr. Stark brings a unique vision to the industry and the Company as a motivated designer of superior approaches to research challenges. Most importantly, Dr. Stark is highly qualified to manage the development opportunities of the company. Formerly the Director of the National Institute of Clinical Research (NICR), Dr. Stark has been responsible for the design, organization and implementation of clinical trials for pharmaceutical and device companies.